1.
Neurology
; 68(9): 688-90, 2007 Feb 27.
Article
in English
| MEDLINE
| ID: mdl-17325277
ABSTRACT
We surveyed neuro-oncologists regarding patients treated with temozolomide for at least 12 cycles or 12 months. Patients receiving first-line temozolomide for a median 13 cycles had a median progression-free survival (PFS) of 14 months. Patients with recurrent disease receiving a median 14 cycles had a median PFS of 15.5 months. A small percentage of patients experienced grade III to IV toxicity. These results suggest that long-term treatment with temozolomide is feasible and well tolerated.
Subject(s)
Brain Neoplasms/drug therapy , Brain Neoplasms/mortality , Dacarbazine/analogs & derivatives , Glioma/drug therapy , Glioma/mortality , Risk Assessment/methods , Adolescent , Adult , Aged , Antineoplastic Agents, Alkylating/administration & dosage , Dacarbazine/administration & dosage , Disease-Free Survival , Feasibility Studies , Female , Humans , Longitudinal Studies , Male , Middle Aged , Risk Factors , Survival Analysis , Survival Rate , Temozolomide , Treatment Outcome
2.
Dis Nerv Syst
; 34(5): 259-62, 1973.
Article
in English
| MEDLINE
| ID: mdl-4782281
